Show notes
Do you like thinking outside the box? How about thinking inside the petri dish?
In a new study from researchers at Johns Hopkins, a team used lab-grown brain cells to test how certain medicines affect patients with Alzheimer’s.
They used blood samples from people with the disease and turned them into stem cells, which they then transformed into brain cells.
These helped them make tiny brains by forming an organoid, a miniature brain that is simpler than a real brain but still mimics how cells are affected by medication, albeit without independent thought.
Having prototype brains to test in a lab before doing clinical trials can be a game-changer for medical research and can help scientists better understand the risks and benefits of a particular medication.
In this study, scientists treated the mini brains with escitalopram oxalate [eh-sih-TAL-o-pram ox-uh-late], a common antidepressant. Often sold as Lexapro, it can be prescribed to patients with Alzheimer’s to help manage symptoms like anxiety, depression and agitation.
The team wanted to see if this type of SSRI could reduce symptoms associated with Alzheimer’s. The study included organoids created from cells from hundreds of patients, including those with Alzheimer’s and those without.
The mini brains made from the cells of people with Alzheimer’s showed more communication between brain cells and better serotonin signaling, which antidepressants are meant to help with.
However, some showed little or no change.
This research could suggest a need for more research that one day can identify patients who would respond well to an individual treatment plan.
Until then, researchers will put their heads — and their lab’s little brains —together to keep searching.